Mike HafeyDepartment of Pharmacokinetics Pharmacodynamics, and Drug Metabolism, Merck & Co., Inc.关注立即认领分享关注立即认领分享基本信息浏览量:0职业迁徙个人简介暂无内容研究兴趣论文共 2 篇作者统计合作学者相似作者按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选时间引用量主题期刊级别合作者合作机构A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 InhibitorsThomas J Tucker,Mark W Embrey,Candice Alleyne,Rupesh P Amin,Alan Bass,Bhavana Bhatt,Elisabetta Bianchi,Danila Branca, Tjerk Bueters,Nicole Buist,Sookhee N Ha,Mike Hafey,JOURNAL OF MEDICINAL CHEMISTRY(2021)引用42浏览0WOS引用420Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluationMatthew L Rizk,Robert Houle,Grace Hoyee Chan,Mike Hafey,Elizabeth G Rhee,Xiaoyan ChuANTIMICROBIAL AGENTS AND CHEMOTHERAPY(2014)引用29浏览0WOS引用290作者统计合作学者合作机构D-Core合作者学生导师暂无相似学者,你可以通过学者研究领域进行搜索筛选数据免责声明页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn